Consolidated Press International Holdings Ltd. Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Consolidated Press International Holdings Ltd. acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,400 shares of the company’s stock, valued at approximately $1,135,000. Medpace comprises about 0.2% of Consolidated Press International Holdings Ltd.’s investment portfolio, making the stock its 13th biggest position.

Other institutional investors also recently bought and sold shares of the company. Cetera Advisors LLC raised its stake in Medpace by 162.4% in the 1st quarter. Cetera Advisors LLC now owns 2,608 shares of the company’s stock worth $1,054,000 after acquiring an additional 1,614 shares during the last quarter. Baillie Gifford & Co. grew its stake in Medpace by 175.6% during the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after purchasing an additional 9,478 shares during the last quarter. Oppenheimer Asset Management Inc. grew its stake in Medpace by 6.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock valued at $15,179,000 after purchasing an additional 2,675 shares during the last quarter. CWA Asset Management Group LLC purchased a new stake in Medpace during the 3rd quarter valued at about $1,306,000. Finally, US Bancorp DE grew its stake in Medpace by 59.3% during the 3rd quarter. US Bancorp DE now owns 8,100 shares of the company’s stock valued at $2,704,000 after purchasing an additional 3,016 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on MEDP shares. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and dropped their price target for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Redburn Atlantic initiated coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 price target on the stock. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Robert W. Baird upped their target price on Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research note on Monday, November 25th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $380.56.

Medpace Trading Up 0.5 %

NASDAQ MEDP opened at $340.63 on Friday. The stock has a market capitalization of $10.59 billion, a price-to-earnings ratio of 29.83, a PEG ratio of 1.88 and a beta of 1.37. Medpace Holdings, Inc. has a twelve month low of $268.80 and a twelve month high of $459.77. The stock has a 50-day moving average of $337.82 and a 200 day moving average of $371.41.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The company had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.22 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.